Disclosure Plus

YUNGJIN PHARM Expands Scope of 'KL1333' Technology Export for the First Time in 9 Years… Additional Transfer of Japanese Licensing Rights

KIM SAE-MI
2026-11-05 14:00:04
[Edaily Reporter KIM SAE-MI ] YUNGJIN PHARM(003520)has expanded the scope of its technology export for “KL1333,” a candidate drug for treating mitochondrial diseases, for the first time in 9 years and 6 months.

YUNGJIN PHARM logo (Photo courtesy of YUNGJIN PHARM)

YUNGJIN PHARM announced on the 5th that it had signed a supplemental agreement with Pharming Technologies B.V. of the Netherlands to transfer additional Japanese rights for KL1333 and expand the scope of technology use.

Under this agreement, the global rights to KL1333 secured by Pharming have been expanded from “worldwide excluding Korea and Japan” to “worldwide excluding Korea.” YUNGJIN PHARM is set to receive an additional upfront payment, milestone payments, and royalties following the transfer of the Japanese rights. Specific amounts and payment terms were not disclosed due to a confidentiality agreement.

Previously, in April 2017, YUNGJIN PHARM licensed KL1333 to Sweden-based NeuroVive Pharmaceutical AB for a total of $57 million (approximately 64.9 billion won at the exchange rate at the time). The upfront payment was $3 million (3.4 billion won), with milestone payments totaling up to $54 million (61.5 billion won), and royalties are separate. The additional revenue from this transfer of Japanese rights is not included in the original contract amount.

Subsequently, the status of the contracting party was transferred from Abliva AB to Farming. In this supplemental agreement, along with the additional transfer of Japanese rights, the scope of technology use for KL1333 was expanded to include pharmaceutically acceptable salts, prodrugs, stereoisomers, and hydrates.

The contract term is also scheduled to be extended from the original December 31, 2039, to May 19, 2047. However, this extension will take effect only after the relevant use patents are registered in individual countries.

An official from YUNGJIN PHARM stated, “To maintain business confidentiality, we have decided to withhold disclosure of the specific terms regarding the upfront payment, milestones, and royalties for the Japanese rights under this supplementary agreement until May 19, 2047.”

Economy

Corporation

IT·Science

Economy

SamsungElectronics Earns 'Top Rating' in Shared Growth Evaluation for 15 Consecutive Years… First Among Korean Companies

SamsungElectronics has become the first South Korean company to receive the highest rating in the Shared Growth Index evaluation for 15 consecutive years. The company was recognized for its contributi…
2026-11-11 12:00:05

Corporation

“Radiopharmaceutical Powerhouse” Cellbion Co., Ltd Heats Up “BioEurope”… Sets Sights on Global Licensing Deal for New Prostate Cancer Drug

#Cellbion Co., Ltd, a company specializing in the development of new radiopharmaceuticals (RPT), is accelerating efforts to secure global technology licensing (L/O) and establish joint development par…
2026-11-11 11:46:02

IT·Science

SKT, KTCorporation Ranks 'Top' on Shared Growth Index for 14 Consecutive Years… Only Two Korean Companies Achieve This

SKTelecom(017670)has once again proven its status as a leading company in Korea committed to mutual growth by earning the highest rating in the Shared Growth Index evaluation for the 14th consecutive …
2026-11-11 12:00:04